Abstract: There is provided a thermosetting powder coating material capable of forming a cured product having excellent workability at coating and high plasticity as well as heat resistance, resulting in heat resistance and crack resistance at bending processing. (A) denotes a bisphenol type epoxy resin having epoxy equivalent weight of 600 to 800 g/eq (not including 800 g/eq), (B) a rubber-modified epoxy resin, (C) a bisphenol type phenyl resin curing agent (D) a compound for activating (C), (D1) an imidazole compound and (D2) an amine-epoxy adduct type compound. The thermosetting powder coating material is composed of a finely pulverized composition. The composition comprises (A), (C) and (D) but does not comprise (B). (D) comprises (D1) and (D2), and a weight ratio of (D2) with respect to (D1) is 1.0 or more and 3.7 or less when (D1) is 1.

Abstract: There is provided a thermosetting powder coating material capable of forming a cured product having excellent workability at coating and high plasticity as well as heat resistance, resulting in heat resistance and crack resistance at bending processing. (A) denotes a bisphenol type epoxy resin having epoxy equivalent weight of 600 to 800 g/eq (not including 800 g/eq), (B) a rubber-modified epoxy resin, (C) a bisphenol type phenyl resin curing agent (D) a compound for activating (C), (D1) an imidazole compound and (D2) an amine-epoxy adduct type compound. The thermosetting powder coating material is composed of a finely pulverized composition. The composition comprises (A), (C) and (D) but does not comprise (B). (D) comprises (D1) and (D2), and a weight ratio of (D2) with respect to (D1) is 1.0 or more and 3.7 or less when (D1) is 1.

Abstract: To provide a new preventive or therapeutic agent for age-related macular degeneration. The present invention relates to a preventive or therapeutic agent for age-related macular degeneration containing a BLT1 antagonist or a LTB4 biosynthesis inhibitor as an active ingredient. The administration form of the preventive or therapeutic agent for age-related macular degeneration of the present invention includes eye drops, injections, oral agents (tablets, granules, dispersions, capsules), ointments, and creams. The form of these pharmaceutical compositions can be formulated by combining with a pharmaceutically acceptable carrier.

Abstract: To provide a new preventive or therapeutic agent for age-related macular degeneration. The present invention relates to a preventive or therapeutic agent for age-related macular degeneration containing a BLT1 antagonist or a LTB4 biosynthesis inhibitor as an active ingredient. The administration form of the preventive or therapeutic agent for age-related macular degeneration of the present invention includes eye drops, injections, oral agents (tablets, granules, dispersions, capsules), ointments, and creams. The form of these pharmaceutical compositions can be formulated by combining with a pharmaceutically acceptable carrier.